Helping people achieve optimal brain states — on-demand.
NeuroLight offers a groundbreaking approach to neuromodulation and brain entrainment to improve sleep and achieve optimal brain states. Building on Crick and Koch’s hypothesis that “every mental state is expressed in neural correlates,” we further hypothesized that inducing brain states’ neural correlates can induce the desired mental state. To this end, we record brainwave activity that occurs during a desired state, and induce this activity in another (or the same subject at a different time) to replicate the desired mental state. We do this via neuromodulation using light and sound.
With this technology and approach, we envision a world where anyone can realize desired brain states on-demand in order to improve their health and optimize performance.
Founder & CEO
Mr. Benjamin has over 20 years experience in medical devices and neurostimulation.
Dr. Zavadsky has more than 30 years experience in technical leadership roles in healthcare and tech.
Mr. Poltorak has over 10 years experience in growth marketing, including medical device cloud connectivity and cognitive assessment software.
Dr. Buff has over 20 years experience in innovation management, technology transfer, IP licensing, and business development.
Healthcare senior executive, MedTech/ medical device startup advisor and investor, and former division president at Thermo Fisher Scientific
Medical device executive, current CTO of AVITA Medical, and former CTO of Boston Scientific Neuromodulation.
Pomona, New York — February 19, 2025 — NeuroLight, Inc., a pioneering neuromodulation medical device company, today announced the appointment of Jeffry B. Lansman, Ph.D.
Pomona, New York — December 2, 2024 — NeuroLight, Inc., a pioneering neuromodulation medical device company, today announced that former Chief Scientist of the US
Dr. Scott Parazynski, an astronaut, inventor, and medical expert, has joined the Advisory Board of NeuroLight, Inc., a neuromodulation medical device company We are thrilled
NeuroLight, Inc. has successfully completed its Phase I NSF/SBIR grant and submitted Outcomes Report, detailing progress in developing neromod sleep technology.
US Patent No. 11,413,425 is issued for non-pharmaceutical treatment of coronasomnia with neuromodulation POMONA, NEW YORK, UNITED STATES, January 31, 2024 — NeuroLight, Inc. today announced
NeuroLight Aims to Use its Technology for Transplanting Mental States to Treat Insomnia and Other Sleep Disorders POMONA, NEW YORK, USA, January 11, 2024 —
© Copyright NeuroLight 2024